The Experts below are selected from a list of 129 Experts worldwide ranked by ideXlab platform

Meyer, Howard S. - One of the best experts on this subject based on the ideXlab platform.

  • GAS/LIQUID MEMBRANES FOR NATURAL GAS UPGRADING
    Gas Technology Institute, 2003
    Co-Authors: Meyer, Howard S.
    Abstract:

    Gas Technology Institute (GTI) is conducting this research program whose objective is to develop gas/liquid membranes for natural gas upgrading to assist DOE in achieving their goal of developing novel methods of upgrading low quality natural gas to meet pipeline specifications. Kvaerner Process Systems (KPS) and W. L. Gore & Associates (GORE) gas/liquid membrane contactors are based on expanded polytetrafluoroethylene (ePTFE) membranes acting as the contacting barrier between the contaminated gas stream and the absorbing liquid. These resilient membranes provide much greater surface area for transfer than other tower internals, with packing densities five to ten times greater, resulting in equipment 50-70% smaller and lower weight for the same treating service. The scope of the research program is to (1) build and install a laboratory- and a field-scale gas/liquid membrane absorber; (2) operate the units with a low quality natural gas feed stream for sufficient time to verify the simulation model of the contactors and to project membrane life in this severe service; and (3) conducted an economic evaluation, based on the data, to quantify the impact of the technology. Chevron, one of the major producers of natural gas, has offered to host the test at a gas treating plant. KPS will use their position as a recognized leader in the construction of commercial amine plants for building the unit along with GORE providing the membranes. GTI will provide operator and data collection support during lab- and field-testing to assure proper analytical procedures are used. Kvaerner and GTI will perform the final economic evaluation. GTI will provide project management and be responsible for reporting and interactions with DOE on this project. Efforts this quarter have concentrated on Legal Agreements, including alternative field sites. Preliminary design of the bench-scale equipment continues

  • GAS/LIQUID MEMBRANES FOR NATURAL GAS UPGRADING
    Gas Technology Institute, 2002
    Co-Authors: Meyer, Howard S.
    Abstract:

    Gas Technology Institute (GTI) is conducting this research program whose objective is to develop gas/liquid membranes for natural gas upgrading to assist DOE in achieving their goal of developing novel methods of upgrading low quality natural gas to meet pipeline specifications. Kvaerner Process Systems (KPS) and W. L. Gore & Associates (GORE) gas/liquid membrane contactors are based on expanded polytetrafluoroethylene (ePTFE) membranes acting as the contacting barrier between the contaminated gas stream and the absorbing liquid. These resilient membranes provide much greater surface area for transfer than other tower internals, with packing densities five to ten times greater, resulting in equipment 50-70% smaller and lower weight for the same treating service. The scope of the research program is to (1) build and install a laboratory- and a field-scale gas/liquid membrane absorber; (2) operate the units with a low quality natural gas feed stream for sufficient time to verify the simulation model of the contactors and to project membrane life in this severe service; and (3) conducted an economic evaluation, based on the data, to quantify the impact of the technology. Chevron, one of the major producers of natural gas, has offered to host the test at a gas treating plant. KPS will use their position as a recognized leader in the construction of commercial amine plants for building the unit along with GORE providing the membranes. GTI will provide operator and data collection support during lab- and field-testing to assure proper analytical procedures are used. KPS and GTI will perform the final economic evaluation. GTI will provide project management and be responsible for reporting and interactions with DOE on this project. Efforts this quarter have concentrated on Legal Agreements, including alternative field sites. Preliminary design of the bench-scale equipment continues

  • GAS/LIQUID MEMBRANES FOR NATURAL GAS UPGRADING
    Gas Technology Institute, 2002
    Co-Authors: Meyer, Howard S.
    Abstract:

    Efforts this quarter have concentrated on Legal Agreements, including alternative field sites. Preliminary design of the bench-scale equipment has been initiated. Gas Technology Institute (GTI) is conducting this research program whose objective is to develop gas/liquid membranes for natural gas upgrading to assist DOE in achieving their goal of developing novel methods of upgrading low quality natural gas to meet pipeline specifications. Kvaerner Process Systems (KPS) and W. L. Gore & Associates (GORE) gas/liquid membrane contactors are based on expanded polytetrafluoroethylene (ePTFE) membranes acting as the contacting barrier between the contaminated gas stream and the absorbing liquid. These resilient membranes provide much greater surface area for transfer than other tower internals, with packing densities five to ten times greater, resulting in equipment 50--70% smaller and lower weight for the same treating service. The scope of the research program is to (1) build and install a laboratory- and a field-scale gas/liquid membrane absorber; (2) operate the units with a low quality natural gas feed stream for sufficient time to verify the simulation model of the contactors and to project membrane life in this severe service; and (3) conducted an economic evaluation, based on the data, to quantify the impact of the technology. Chevron, one of the major producers of natural gas, has offered to host the test at a gas treating plant. KPS will use their position as a recognized leader in the construction of commercial amine plants for building the unit along with GORE providing the membranes. GTI will provide operator and data collection support during lab- and field-testing to assure proper analytical procedures are used. Kvaerner and GTI will perform the final economic evaluation. GTI will provide project management and be responsible for reporting and interactions with DOE on this project

  • GAS/LIQUID MEMBRANES FOR NATURAL GAS UPGRADING
    Gas Technology Institute, 2002
    Co-Authors: Meyer, Howard S.
    Abstract:

    A new project was initiated this quarter to develop gas/liquid membranes for natural gas upgrading. Efforts have concentrated on Legal Agreements, including alternative field sites. Gas Technology Institute (GTI) is conducting this research program whose objective is to develop gas/liquid membranes for natural gas upgrading to assist DOE in achieving their goal of developing novel methods of upgrading low quality natural gas to meet pipeline specifications. Kvaerner Process Systems (KPS) and W. L. Gore & Associates (GORE) gas/liquid membrane contactors are based on expanded polytetrafluoroethylene (ePTFE) membranes acting as the contacting barrier between the contaminated gas stream and the absorbing liquid. These resilient membranes provide much greater surface area for transfer than other tower internals, with packing densities five to ten times greater, resulting in equipment 50-70% smaller and lower weight for the same treating service. The scope of the research program is to (1) build and install a laboratory- and a field-scale gas/liquid membrane absorber; (2) operate the units with a low quality natural gas feed stream for sufficient time to verify the simulation model of the contactors and to project membrane life in this severe service; and (3) conducted an economic evaluation, based on the data, to quantify the impact of the technology. Chevron, one of the major producers of natural gas, has offered to host the test at a gas treating plant. KPS will use their position as a recognized leader in the construction of commercial amine plants for building the unit along with GORE providing the membranes. GTI will provide operator and data collection support during lab- and field-testing to assure proper analytical procedures are used. Kvaerner and GTI will perform the final economic evaluation. GTI will provide project management and be responsible for reporting and interactions with DOE on this project

David M Studdert - One of the best experts on this subject based on the ideXlab platform.

  • academic medical centers standards for clinical trial Agreements with industry
    2005
    Co-Authors: Michelle M Mello, Brian Clarridge, David M Studdert
    Abstract:

    Background: Although industry sponsors provide approximately 70 percent of the funding for clinical drug trials in the United States, little is known about the Legal Agreements that exist between industry sponsors and academic investigators. We studied institutional standards regarding contractual provisions that restrict investigators' control over trials. Methods: We used a structured, cross-sectional mail survey of medical-school research administrators responsible for negotiating clinical-trial Agreements with industry sponsors. Results: Of 122 institutions approached, 107 participated. There was a high degree of consensus among administrators about the acceptability of several contractual provisions relating to publications. For example, more than 85 percent reported that their office would not approve provisions giving industry sponsors the authority to revise manuscripts or decide whether results should be published. There was considerable disagreement about the acceptability of provisions allowing the sponsor to insert its own statistical analyses in manuscripts (24 percent allowed them, 47 percent disallowed them, and 29 percent were not sure whether they should allow them), draft the manuscript (50 percent allowed it, 40 percent disallowed it, and 11 percent were not sure whether they should allow it), and prohibit investigators from sharing data with third parties after the trial is over (41 percent allowed it, 34 percent disallowed it, and 24 percent were not sure whether they should allow it). Disputes were common after the Agreements had been signed and most frequently centered on payment (75 percent of administrators reported at least one such dispute in the previous year), intellectual property (30 percent), and control of or access to data (17 percent). Conclusions: Standards for certain restrictive provisions in clinical-trial Agreements with industry sponsors vary considerably among academic medical centers. Greater sharing of information about Legal relationships with industry sponsors is desirable in order to build consensus about appropriate standards.

  • academic medical centers standards for clinical trial Agreements with industry
    The New England Journal of Medicine, 2005
    Co-Authors: Michelle M Mello, Brian Clarridge, David M Studdert
    Abstract:

    background Although industry sponsors provide approximately 70 percent of the funding for clinical drug trials in the United States, little is known about the Legal Agreements that exist between industry sponsors and academic investigators. We studied institutional standards regarding contractual provisions that restrict investigators’ control over trials. methods We used a structured, cross-sectional mail survey of medical-school research administrators responsible for negotiating clinical-trial Agreements with industry sponsors. results

Michelle M Mello - One of the best experts on this subject based on the ideXlab platform.

  • academic medical centers standards for clinical trial Agreements with industry
    2005
    Co-Authors: Michelle M Mello, Brian Clarridge, David M Studdert
    Abstract:

    Background: Although industry sponsors provide approximately 70 percent of the funding for clinical drug trials in the United States, little is known about the Legal Agreements that exist between industry sponsors and academic investigators. We studied institutional standards regarding contractual provisions that restrict investigators' control over trials. Methods: We used a structured, cross-sectional mail survey of medical-school research administrators responsible for negotiating clinical-trial Agreements with industry sponsors. Results: Of 122 institutions approached, 107 participated. There was a high degree of consensus among administrators about the acceptability of several contractual provisions relating to publications. For example, more than 85 percent reported that their office would not approve provisions giving industry sponsors the authority to revise manuscripts or decide whether results should be published. There was considerable disagreement about the acceptability of provisions allowing the sponsor to insert its own statistical analyses in manuscripts (24 percent allowed them, 47 percent disallowed them, and 29 percent were not sure whether they should allow them), draft the manuscript (50 percent allowed it, 40 percent disallowed it, and 11 percent were not sure whether they should allow it), and prohibit investigators from sharing data with third parties after the trial is over (41 percent allowed it, 34 percent disallowed it, and 24 percent were not sure whether they should allow it). Disputes were common after the Agreements had been signed and most frequently centered on payment (75 percent of administrators reported at least one such dispute in the previous year), intellectual property (30 percent), and control of or access to data (17 percent). Conclusions: Standards for certain restrictive provisions in clinical-trial Agreements with industry sponsors vary considerably among academic medical centers. Greater sharing of information about Legal relationships with industry sponsors is desirable in order to build consensus about appropriate standards.

  • academic medical centers standards for clinical trial Agreements with industry
    The New England Journal of Medicine, 2005
    Co-Authors: Michelle M Mello, Brian Clarridge, David M Studdert
    Abstract:

    background Although industry sponsors provide approximately 70 percent of the funding for clinical drug trials in the United States, little is known about the Legal Agreements that exist between industry sponsors and academic investigators. We studied institutional standards regarding contractual provisions that restrict investigators’ control over trials. methods We used a structured, cross-sectional mail survey of medical-school research administrators responsible for negotiating clinical-trial Agreements with industry sponsors. results

Tania Bubela - One of the best experts on this subject based on the ideXlab platform.

  • Legal Agreements and the governance of research commons lessons from materials sharing in mouse genomics
    Omics A Journal of Integrative Biology, 2014
    Co-Authors: Amrita Mishra, Tania Bubela
    Abstract:

    Omics research infrastructure such as databases and bio-repositories requires effective governance to support pre-competitive research. Governance includes the use of Legal Agreements, such as Material Transfer Agreements (MTAs). We analyze the use of such Agreements in the mouse research commons, including by two large-scale resource development projects: the International Knockout Mouse Consortium (IKMC) and International Mouse Phenotyping Consortium (IMPC). We combine an analysis of Legal Agreements and semi-structured interviews with 87 members of the mouse model research community to examine Legal Agreements in four contexts: (1) between researchers; (2) deposit into repositories; (3) distribution by repositories; and (4) exchanges between repositories, especially those that are consortium members of the IKMC and IMPC. We conclude that Legal Agreements for the deposit and distribution of research reagents should be kept as simple and standard as possible, especially when minimal enforcement capacity and resources exist. Simple and standardized Legal Agreements reduce transactional bottlenecks and facilitate the creation of a vibrant and sustainable research commons, supported by repositories and databases.

Brian Clarridge - One of the best experts on this subject based on the ideXlab platform.

  • academic medical centers standards for clinical trial Agreements with industry
    2005
    Co-Authors: Michelle M Mello, Brian Clarridge, David M Studdert
    Abstract:

    Background: Although industry sponsors provide approximately 70 percent of the funding for clinical drug trials in the United States, little is known about the Legal Agreements that exist between industry sponsors and academic investigators. We studied institutional standards regarding contractual provisions that restrict investigators' control over trials. Methods: We used a structured, cross-sectional mail survey of medical-school research administrators responsible for negotiating clinical-trial Agreements with industry sponsors. Results: Of 122 institutions approached, 107 participated. There was a high degree of consensus among administrators about the acceptability of several contractual provisions relating to publications. For example, more than 85 percent reported that their office would not approve provisions giving industry sponsors the authority to revise manuscripts or decide whether results should be published. There was considerable disagreement about the acceptability of provisions allowing the sponsor to insert its own statistical analyses in manuscripts (24 percent allowed them, 47 percent disallowed them, and 29 percent were not sure whether they should allow them), draft the manuscript (50 percent allowed it, 40 percent disallowed it, and 11 percent were not sure whether they should allow it), and prohibit investigators from sharing data with third parties after the trial is over (41 percent allowed it, 34 percent disallowed it, and 24 percent were not sure whether they should allow it). Disputes were common after the Agreements had been signed and most frequently centered on payment (75 percent of administrators reported at least one such dispute in the previous year), intellectual property (30 percent), and control of or access to data (17 percent). Conclusions: Standards for certain restrictive provisions in clinical-trial Agreements with industry sponsors vary considerably among academic medical centers. Greater sharing of information about Legal relationships with industry sponsors is desirable in order to build consensus about appropriate standards.

  • academic medical centers standards for clinical trial Agreements with industry
    The New England Journal of Medicine, 2005
    Co-Authors: Michelle M Mello, Brian Clarridge, David M Studdert
    Abstract:

    background Although industry sponsors provide approximately 70 percent of the funding for clinical drug trials in the United States, little is known about the Legal Agreements that exist between industry sponsors and academic investigators. We studied institutional standards regarding contractual provisions that restrict investigators’ control over trials. methods We used a structured, cross-sectional mail survey of medical-school research administrators responsible for negotiating clinical-trial Agreements with industry sponsors. results